RxElite, Inc. Announces Implementation of Preferred Contract Awarded With Heritage Valley Health System for Their Anesthetic Gas
07 7월 2008 - 9:30PM
Marketwired
MERIDIAN, ID is pleased to announce it has completed
implementation of the contract, and has received orders from
Heritage Valley Health Systems, for their anesthetic gas products.
RxElite was awarded a preferred contract listing in all classes of
trade for Sevoflurane (Sojourn(TM)) and Isoflurane (Terrell(TM)) on
March 3, 2008. Sevoflurane is the most commonly used anesthetic gas
in the U.S. and Isoflurane continues to hold share in the
anesthetic gas market.
"We are excited to partner with Heritage Valley and do our part
in helping our customers lower costs in the current economic
environment. The agreement has already begun to yield cost savings
to their health system," stated Jonathan Houssian, the CEO of
RxElite.
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic
prescription drug products in specialty generic markets. These
markets include products in the areas of anesthesia, sterile liquid
dose drugs (including respiratory inhalation drugs, ophthalmics,
and injectable drugs), complex active pharmaceutical ingredients,
and other specialty areas. www.RxElite.com
About Heritage Valley Health System
Heritage Valley Health System provides comprehensive health care
for residents of Allegheny, Beaver, Butler and Lawrence counties,
in Pennsylvania; eastern Ohio; and the panhandle of West Virginia.
In partnership with more than 400 physicians, Heritage Valley
offers a broad range of medical, surgical and diagnostic services
at its two hospitals, Heritage Valley Beaver, and Heritage Valley
Sewickley; in physician offices; and community satellite
facilities. Additional information about Heritage Valley Health
System is available online at www.heritagevalley.org.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
involving known and unknown risks, delays, and uncertainties that
may cause our actual results or performance to differ materially
from those expressed or implied by these forward-looking
statements. These risks, delays, and uncertainties include, but are
not limited to: risks associated with the uncertainty of future
financial results, our reliance on our sole supplier, the limited
diversification of our product offerings, additional financing
requirements, development of new products, government approval
processes, the impact of competitive products or pricing,
technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities
and Exchange Commission. The Company undertakes no obligation to
update any forward-looking statements.
For more information: Corporate Information US T: (208) 288-5550
Toll Free: (800) 414-1901 F: (208) 288-1191 Investor Relations Ric
Tener T: (208) 288-5550 Fax: (208) 288-1191 Email: Email
Contact
RXElite (CE) (USOTC:RXEI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
RXElite (CE) (USOTC:RXEI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
